Literature DB >> 18025878

The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia.

Marian P Laderoute1, Antonio Giulivi, Louise Larocque, Deana Bellfoy, Yangxun Hou, Hong-Xing Wu, Keith Fowke, Jun Wu, Francisco Diaz-Mitoma.   

Abstract

OBJECTIVE: To address the activation and replicative activity of HERV-K102 in vivo associated with HIV viremia. DESIGN AND METHODS: Initially serology was performed on HERV-K102 specific envelope peptides to determine if HERV-K102 may become activated with HIV viremia. Before developing a quantitative PCR (qPCR) assay, we first determined whether plasma associated particles contained DNA or RNA genomes in a pilot study which surprisingly revealed predominantly DNA genomes. A relative, ddCt qPCR ratio method was then devised to detect excess levels of HERV-K102 pol DNA templates over genomic levels which served as a surrogate marker to reliably index the level of particles found in plasma.
RESULTS: Both the peptide serology and ddCt qPCR excess ratio methods suggested the activation of HERV-K102 in about 70-80% of HIV viremic cases whereas only 2-3% of normal healthy adults had marginally activated HERV-K102 (P < 0.0001). Moreover, by digestion with dUTPase we were able to confirm that the vast majority of excess DNA template in plasma related to cDNA production rather than representing genomic copies.
CONCLUSIONS: Our work uniquely suggests the common activation of HERV-K102 with HIV viremia and may be first to directly demonstrate HERV-K102 cDNA production in vivo. The potential implications of the induction of HERV-K102 activation and replication for the prevention and control of HIV are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025878     DOI: 10.1097/QAD.0b013e3282f14d64

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  26 in total

1.  Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.

Authors:  Marta J Gonzalez-Hernandez; Michael D Swanson; Rafael Contreras-Galindo; Sarah Cookinham; Steven R King; Richard J Noel; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis.

Authors:  Renée Douville; Jiankai Liu; Jeffrey Rothstein; Avindra Nath
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects.

Authors:  Ravi Tandon; Devi SenGupta; Lishomwa C Ndhlovu; Raphaella G S Vieira; R Brad Jones; Vanessa A York; Vinicius A Vieira; Elizabeth R Sharp; Andrew A Wiznia; Mario A Ostrowski; Michael G Rosenberg; Douglas F Nixon
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

4.  Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic.

Authors:  Jonah B Sacha; In-Jeong Kim; Lianchun Chen; Jakir H Ullah; David A Goodwin; Heather A Simmons; Daniel I Schenkman; Frederike von Pelchrzim; Robert J Gifford; Francesca A Nimityongskul; Laura P Newman; Samantha Wildeboer; Patrick B Lappin; Daisy Hammond; Philip Castrovinci; Shari M Piaskowski; Jason S Reed; Kerry A Beheler; Tharsika Tharmanathan; Ningli Zhang; Sophie Muscat-King; Melanie Rieger; Carla Fernandes; Klaus Rumpel; Joseph P Gardner; Douglas H Gebhard; Juliann Janies; Ahmed Shoieb; Brian G Pierce; Dusko Trajkovic; Eva Rakasz; Sing Rong; Michael McCluskie; Clare Christy; James R Merson; R Brad Jones; Douglas F Nixon; Mario A Ostrowski; Peter T Loudon; Ingrid M Pruimboom-Brees; Neil C Sheppard
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

Review 5.  Human endogenous retrovirus-K (HML-2): a comprehensive review.

Authors:  Marta Garcia-Montojo; Tara Doucet-O'Hare; Lisa Henderson; Avindra Nath
Journal:  Crit Rev Microbiol       Date:  2018-10-14       Impact factor: 7.624

6.  Genomic flexibility of human endogenous retrovirus type K.

Authors:  Derek Dube; Rafael Contreras-Galindo; Shirley He; Steven R King; Marta J Gonzalez-Hernandez; Scott D Gitlin; Mark H Kaplan; David M Markovitz
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 7.  Human endogenous retroviruses and the nervous system.

Authors:  Renée N Douville; Avindra Nath
Journal:  Handb Clin Neurol       Date:  2014

8.  Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer.

Authors:  Rafael Contreras-Galindo; Mark H Kaplan; Philippe Leissner; Thibault Verjat; Ilaria Ferlenghi; Fabio Bagnoli; Fabiola Giusti; Michael H Dosik; Daniel F Hayes; Scott D Gitlin; David M Markovitz
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

9.  HIV-1 interacts with human endogenous retrovirus K (HML-2) envelopes derived from human primary lymphocytes.

Authors:  Daria Brinzevich; George R Young; Robert Sebra; Juan Ayllon; Susan M Maio; Gintaras Deikus; Benjamin K Chen; Ana Fernandez-Sesma; Viviana Simon; Lubbertus C F Mulder
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

10.  Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy.

Authors:  M Garcia-Montojo; S Fathi; G Norato; B R Smith; D B Rowe; M C Kiernan; S Vucic; S Mathers; R P A van Eijk; U Santamaria; M-L Rogers; A Malaspina; V Lombardi; P R Mehta; H-J Westeneng; L H van den Berg; A Al-Chalabi; J Gold; A Nath
Journal:  J Neurol Sci       Date:  2021-02-23       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.